Researcher
Vigor Van Tendeloo
- Keywords:Medicine
- Disciplines:Innate immunity, Cancer therapy, Hematology, Vaccinology
Affiliations
- Laboratory for Experimental Hematology (LEH) (Research group)
Member
From1 Jan 2019 → 31 Dec 2023 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2003 → 31 Dec 2018
Projects
1 - 10 of 31
- Preclinical development of a next-generation CAR-T cell therapy for multiple myeloma.From1 Nov 2019 → 31 Oct 2020Funding: Nonprofit institution or equivalents
- Immune effector cell therapy for hematological malignancies with a focus on acute myeloid leukemia and multiple myeloma.From1 Oct 2019 → TodayFunding: FWO fundamental clinical research fellowship
- Vaccine & Infectious Diseases Excellence in Antwerp: Infectious disease prevention, control and management in a One Health policy context (VAX-IDEA).From3 Jul 2019 → 31 Dec 2023Funding: BOF - Methusalem, Fund Recuperation Fiscal Exemption
- Preclinical development of a next-generation CAR-T cell therapy for multiple myeloma.From2 Jul 2019 → 1 Jul 2020Funding: Foundations, funds and other with scientific goal
- Unlocking the TCR repertoire for personalized cancer immunotherapies.From1 Jan 2019 → 31 Dec 2022Funding: FWO Strategic Basic Research Grant
- Improved RNA-based engineering of T lymphocytes with leukemia-specific T cell receptors to redirect their effector functions: towards a clinically safe platform to evaluate efficacy and potential off-target toxicity.From1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- An interdisciplinary study on the role of the HLA genes and T-cell diversity as risk factors for herpes zoster.From1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- Harnessing the expression of interleukin-15 and CD56 in immunotherapeutic strategies combating leukemia: a functional and mechanistic characterizationFrom1 Oct 2017 → 12 May 2019Funding: FWO fellowships
- Wilms' tumor 1-specific T cell receptor (TCR) RNA-modified T cells for adoptive immunotherapy of cancer : moving towards clinical application.From1 Jan 2017 → 31 Dec 2018Funding: Foundations, funds and other with scientific goal
- Maximizing the anti-tumor potency of next-generation dendritic cell vaccines by combining interleukin-15 and in situ silencing of programmed-death ligands.From1 Jan 2017 → 31 Dec 2020Funding: FWO Strategic Basic Research Grant
Publications
21 - 30 of 125
- Memory $CD4^{+}$ T cell receptor repertoire data mining as a tool for identifying cytomegalovirus serostatus(2019)
Authors: Nicolas De Neuter, Esther Bartholomeus, George Elias, Nina Keersmaekers, Arvid Suls, Evelien Smits, Niel Hens, Philippe Beutels, Pierre Van Damme, Geert Mortier, et al.
Pages: 255 - 260 - Tracking dye-independent approach to identify and isolate in vitro expanded T cells(2019)
Authors: George Elias, Benson Ogunjimi, Vigor Van Tendeloo
- Dendritic cell-based immunotherapy of acute myeloid leukemia(2019)
Authors: Heleen Van Acker, Maarten Versteven, Felix S. Lichtenegger, Gils Roex, Diana Campillo Davó, Eva Lion, Marion Subklewe, Vigor Van Tendeloo, Zwi Berneman, Sébastien Anguille
- Dendritic cell-based and other vaccination strategies for pediatric cancer(2019)
Authors: Sévérine de Bruijn, Sébastien Anguille, Joris Verlooy, Evelien Smits, Vigor Van Tendeloo, Maxime De Laere, Koenraad Norga, Zwi Berneman, Eva Lion
- CD56 homodimerization and participation in anti-tumor immune effector cell functioning(2019)
Authors: Heleen Van Acker, Zoë Van Acker, Maarten Versteven, Peter Ponsaerts, Daniela Pende, Zwi Berneman, Sébastien Anguille, Vigor Van Tendeloo, Evelien Smits
- The role of the common gamma-chain family cytokines in $\gamma\delta$ T cell-based anti-cancer immunotherapy(2018)
Authors: Heleen Van Acker, Diana Campillo Davó, Gils Roex, Maarten Versteven, Evelien Smits, Vigor Van Tendeloo
Pages: 54 - 64 - Dendritic cells and programmed death-1 blockade(2018)
Authors: Maarten Versteven, Johan Van den Bergh, Elly Marcq, Evelien Smits, Vigor Van Tendeloo, Willemijn Hobo, Eva Lion
- Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity(2018)
Authors: Pieter Meysman, Nicolas De Neuter, Esther Bartholomeus, George Elias, Johan Van den Bergh, Marie-Paule Emonds, Geert W. Haasnoot, Steven Heynderickx, Johan Wens, Nele Michels, et al.
Pages: 363 - 372 - On the feasibility of mining CD8+ T cell receptor patterns underlying immunogenic peptide recognition(2018)
Authors: Nicolas De Neuter, Wout Bittremieux, Charlie Beirnaert, Bart Cuypers, Aida Ligata (Mrzic), Pieter Moris, Arvid Suls, Vigor Van Tendeloo, Benson Ogunjimi, Kris Laukens, et al.
Pages: 159 - 168 - Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing(2018)
Authors: Diana Campillo Davó, Fumihiro Fujiki, Johan Van den Bergh, Hans De Reu, Evelien Smits, Haruo Sugiyama, Eva Lion, Vigor Van Tendeloo
Patents
1 - 1 of 1
Linked dataset
1 - 1 of 1